Two distinct pathways leading to the development of septic shock pave the way for personalized medicine in sepsis

2021-02-18

(Press-News.org) Researchers have published new insights into the causes of mortality in sepsis Loss of endothelial function is induced through two different pathophysiological processes and is a major driver of septic shock, a life-threatening drop in blood pressure The first pathway originates in the loss of the endothelial barrier triggering an increased production of the repair hormone bioactive Adrenomedullin (bio-ADM), which also has the undesired side effect of vasodilation The second threat acting on the endothelial function is the release of the protease DPP3 into the bloodstream which degrades angiotensin II, a process resulting in decreased vascular tone and cardiac output The different pathways require different treatment strategies thus opening new approaches for personalized medicine in sepsis New diagnostics for quantification of bio-ADM and DPP3 are available as laboratory and near-patient rapid tests Biomarker-guided approaches for therapies targeting these pathways are showing promising results

Hennigsdorf/Berlin, Germany, February 18, 2021 - Diagnostics company SphingoTec GmbH (SphingoTec) announced today that two distinct processes are involved in the development of septic shock and that SphingoTec's biomarkers for endothelial function (vascular integrity) and cardiovascular depression allow early identification of these underlying mechanisms requiring different interventions. Sepsis, a global burden with nearly 50 million cases worldwide, is a life-threatening condition that is diagnostically and therapeutically underserved. With the availability of such pathway-specific biomarkers, new avenues for diagnosing and monitoring sepsis are opened and biomarker-guided trials for personalized therapies targeting these mechanisms are enabled.

Researchers have summarized the available evidence (1) on two distinct pathophysiological processes leading to endothelial dysfunction and the subsequent development of shock and organ failure in sepsis. The two biologically active molecules acting on the vasculature and influencing patient outcomes are bioactive Adrenomedullin (bio-ADM) and Dipeptidyl peptidase 3 (DPP3). One distinct pathway originates in the loss of endothelial barrier integrity, causing edema and the loss of intravascular volume. To compensate for this leakage, the production of the repair hormone bio-ADM is increased. But bio-ADM has also the second function of vascular relaxation, therefore the increased production leads to a dangerous side effect of vasodilation, generating a loss of tissue resistance which ultimately culminates in shock. Data from the observational study AdrenOSS-1 show (3) that elevations of bio-ADM levels reflect the loss of endothelial function and translate into poor outcome in sepsis. Furthermore, the results of the biomarker-guided AdrenOSS-2 trial (2) confirm that this pathway is a valid therapeutic target. According to the second underlying mechanism accountable for the loss of the endothelial function, the depletion of angiotensin II affects the renin-angiotensin-aldosterone system (RAAS), ultimately leading to a cardiovascular depression (4,5) and reduced vascular tone, a deadly combination in need of selective treatment strategies. The main process generating the depletion of the cardiovascular stimulating hormone angiotensin II is the release of the protease DPP3 into the bloodstream through sepsis-induced cell damage (6).

Personalized medicine has shown significant progress in areas such as oncology or cardiology, but in intensive care units, it has remained challenging to identify biomarkers that facilitate personalized treatments. In the context of a life-threatening condition such as septic shock, taking therapeutic decisions is time-critical, aiming to respond in the best possible way and especially on a patient-specific basis. The review (1) summarizes that the biomarkers bio-ADM and DPP3 can identify these pathways, supporting an early and precise diagnosis and monitoring of sepsis patients. Moreover, data from the biomarker-guided interventional study AdrenOSS-2 show that clinical trials can benefit from the use of biomarker as an enrichment strategy. Within the AdrenOSS-2 study, patients with sepsis-associated endothelial dysfunction were identified by increased bio-ADM to receive therapy with placebo or Adrecizumab (2), an antibody targeting the loss of vascular integrity by maintaining protective bio-ADM concentrations in the blood. When excluding patients with additionally high DPP3 blood concentrations, outcomes could further be improved. Therapies blocking DPP3-activity have also been shown to improve outcomes in various preclinical models. (7)

Dr. Andreas Bergmann, founder of various companies fighting sepsis mortality and CEO of critical care diagnostics company SphingoTec commented: "Following a deep understanding of the disease biology, we have developed diagnostic solutions that can now unravel the etiology of the mortality drivers in sepsis. The evidence confirms the utility of our biomarkers in supporting clinicians make more informed decisions and ultimately improve patient management. "

The new diagnostics for quantification of bio-ADM and DPP3 are available as microtiter plate assays as well as point-of-care tests on the Nexus IB10 immunoassay platform. The Nexus IB10 analyzer provides test results on whole blood samples in only 20 minutes and can be flexibly deployed in emergency departments, intensive care units, and any laboratory setting.

INFORMATION:

References (1) van Lier (2020), Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3, J. Intern. Med., DOI: https://doi.org/10.1111/joim.13220 (2) Geven et al (2019)A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2), BMJ, DOI: 10.1136/bmjopen-2018-024475 (3) Mebazaa (2018), Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study , Crit Care DOI: (4) Jha et al (2020), Dipeptidyl peptidase 3 modulates the renin-angiotensin system in mice, J Biol Chem., DOI: 10.1074/jbc.RA120.014183. (5) Takagi et al (2020), Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial, Eur J Heart Fail, DOI: 10.1002/ejhf.1600 (6) Bet et al (2021) Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care DOI: https://doi.org/10.1186/s13054-021-03471-2 (7) Deniau et al (2020) Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics, Eur J Heart Fail, DOI: 10.1002/ejhf.1601.

About SphingoTec SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. SphingoTec's proprietary biomarker portfolio includes bioactive Adrenomedullin (bio-ADM), a biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid), a biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a biomarker for cardiac depression. IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest® microtiter plate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.

About bio-ADM® sphingotest® bio-ADM® measures bioactive Adrenomedullin (bio-ADM), a hormone maintaining endothelial function. The endothelium contributes to blood pressure and separates blood from the surrounding tissue. Elevated blood levels of bio-ADM® predict blood pressure break down and leaky vessels resulting in oedema. Imbalanced endothelial function is the major cause of shock ultimately resulting in organ dysfunction and death. Early identification of an imbalance in endothelial function allows guidance of vasopressor and diuretic therapy in critically ill patients to improve outcomes. Learn more about bio-ADM® at http://www.sphingotec.com

About DPP3 sphingotest® DPP3 measures Dipeptidyl peptidase 3 an active enzyme which, when released into the blood, inactivates angiotensin II, a hormone that is important for heart function. The depletion of angiotensin II affects the renin-angiotensin-aldosterone system (RAAS), ultimately leading to cardiovascular depression and reduced vascular tone, a deadly combination in need of selective treatment strategies. The DPP3 release is a newly identified disease mechanism explaining short-term organ failure in critically ill patients. Early identification of DPP3 release may allow better patient stratification and earlier therapy escalation to improve outcomes. http://www.sphingotec.com

ELSE PRESS RELEASES FROM THIS DATE:

First COVID-19 lockdown cost UK hospitality and high street £45 billion in turnover, researchers estimate

2021-02-18

The UK's first national lockdown from March 2020 and its immediate aftermath saw a massive shift in consumer habits that was initially mandated but then lingered as shops and restaurants opened but risks from the virus remained. A new study from the universities of Cambridge and Newcastle used data from the ONS to compare retail, hospitality and online sales in the UK between March and August 2020 with average figures for the same months for the years 2010-2019. Researchers took an approach normally used to estimate cumulative excess deaths to try and measure the impact of the COVID-19 shock on sales of UK retailers and restaurants. They say their economic models suggest that shops predominantly selling food, such as supermarkets, saw ...

New recommendations aim to eliminate racial bias in myeloma trials

2021-02-18

Researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) are releasing recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites. The initiative, publishing today in the AACR journal Blood Cancer Discovery, is a "road map" for designing myeloma clinical trials to eliminate racial bias by including more African American patients, as well as gathering "real-world" data from health records about the effects of drugs in African American patients. Through this joint workshop initiated by ...

Setting hospital prices would save more than increasing competition or price transparency

2021-02-18

Among strategies to curb hospital prices among the commercially insured population in the U.S., direct price regulations such as setting rates are likely to achieve greater savings than other approaches like increasing competition or improving price transparency, according to a new RAND Corporation study. But price regulations face the greatest political obstacles and historically have been strongly opposed by medical providers, according to the report. Setting prices for all commercial health care payers could reduce hospital spending by $61.9 billion to $236.6 billion annually if the rates were set as high as 150% to as low as 100% of the amounts paid by the federal Medicare program, ...

Study examines aspirin and statin use among older Americans

2021-02-18

An analysis published in the Journal of the American Geriatrics Society indicates that while adults aged 75 years and older do not benefit from taking aspirin to prevent cardiovascular disease, many do so on a regular basis. Also, although statins are known to help prevent heart problems in older adults who have experienced a cardiovascular event, many of these individuals do not take a statin. The analysis included data on 11,392 U.S. adults aged 50 years and older who were surveyed from 2011 to 2018. Investigators found that more than half of participants took aspirin or a statin. "Healthcare providers should inform their older patients about appropriate aspirin use so that they can avoid misuse of aspirin, which can be easily purchased over the counter. Ultimately, ...

Addressing the biological causes of racial disparities in prostate cancer

2021-02-18

African Americans have higher rates of prostate cancer and are more likely to die from the disease than other groups in the United States, likely due to socioeconomic factors, healthcare access problems, and tumor biology. A new review published in Cancer Reports focuses on the biological differences in the development of prostate cancer across ethnicities. The authors note that these differences could be leveraged to improve the diagnosis and treatment of prostate cancer in African American men, ultimately reducing incidence and mortality rates associated with the disease. "We provide a comprehensive review of the significant research in recent years that has examined the molecular and genomic reasons for unequal cancer burden in African American and Caucasian American ...

Real world data on hospital readmissions of patients with heart failure

2021-02-18

In an analysis of information on 448 patients with heart failure who were discharged from a hospital in Sweden, 20.3% of patients were readmitted to the hospital within 30 days, and 60.9% were readmitted within 1 year. The END ...

Oil spill has long-term immunological effects in dolphins

2021-02-18

A study published in Environmental Toxicology and Chemistry has found long-term impacts of the 2010 Deepwater Horizon oil spill in the northern Gulf of Mexico on bottlenose dolphins' immune function. Bottlenose dolphins from an area that received prolonged and heavy oiling were temporarily captured, sampled, and released as part of health assessment programs. The animals were compared with dolphins from an area where no oil was observed. Investigators documented immunological alterations in bottlenose dolphins tested up to a decade following the oil spill that were similar in nature to those immediately following the spill. The effects were seen even in dolphins born after the spill. The nature of the immunological ...

How likely are consumers to adopt artificial intelligence for banking advice?

2021-02-18

A new study published in Economic Inquiry is the first to assess the willingness of consumers to adopt advisory services in the banking sector that are based on artificial intelligence (AI). Investigators examined whether the likelihood that consumers adopt AI in banking services depends on tastes for human interaction across different cultures. The study focused on robo-advisory services, which are automated investment platforms that provide investment advice without the intervention of a human advisor. When investigators analyzed an ING Bank dataset encompassing 11,000 respondents from 11 countries, they found ...

Certain factors are linked with an elevated risk of bone fractures

2021-02-18

A new study published in the Journal of Bone and Mineral Research has identified various factors that may indicate whether a person faces a higher likelihood of experiencing a bone fracture over the next two decades. The study included 30,446 middle-aged women and men who were followed from the early/mid 1990s to 2016. A total of 8,240 participants (27%) had at least one fracture during a median follow-up of 20.7 years. Older age, female sex, higher body mass index, a previous fracture, a family history of fracture after the age of 50 years, low leisure-time physical activity, heavy work, living alone, smoking, and no or high alcohol consumption were factors independently associated with ...

Physical conditions linked to psychological distress in patients with cancer

2021-02-18

Among patients with cancer, having additional physical comorbidities was linked with a higher risk of experiencing psychological distress. The finding comes from a Psycho-Oncology analysis of 2017 data from the National Health Survey of Spain. The analysis included 484 patients who reported a cancer diagnosis and 484 matched controls without a history of cancer. Compared with controls, patients with cancer reported more physical comorbidities, including chronic back pain, asthma, chronic bronchitis, urinary incontinence, prostate problems, and kidney problems. ...

LAST 30 PRESS RELEASES:

Amid record year for dengue infections, new study finds climate change responsible for 19% of today’s rising dengue burden

New study finds air pollution increases inflammation primarily in patients with heart disease

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski